Healthcare Industry News: Bristol-Myers Squibb
News Release - June 22, 2017
Biohaven Broadens Senior Leadership Team With Veteran Pharma ExecutivesNEW HAVEN, Conn., June 22, 2017 -- (Healthcare Sales & Marketing Network) -- (NYSE: BHVN) - Biohaven Pharmaceutical Holding Company Ltd. (Biohaven) and it's wholly owned subsidiary, Biohaven Pharmaceuticals, Inc., today announced recent key additions to its senior leadership team as it develops an expanded portfolio of therapeutic candidates across multiple neurological disorders. Elyse Stock, M.D. has been appointed as the company's Chief of Portfolio Strategy and Development, and St. John (Donnie) McGrath, M.D. has been appointed as Chief of Corporate Strategy and Business Development.
"With their strong records of success, Elyse and Donnie will augment our leadership team as we advance the development of our five lead compounds and continue to build a broad portfolio of innovative therapies for patients with severe and untreated disorders," said Vlad Coric, M.D., CEO of Biohaven. "Elyse will drive the completion of our clinical and pre-clinical programs toward commercialization, while Donnie will lead our external business relationships and drive corporate strategy."
Elyse Stock, M.D., Chief of Portfolio Strategy and Development at BiohavenSt. John (Donnie) McGrath, M.D., Chief of Corporate Strategy and Business Development at BiohavenVlad Coric M.D., Chief Executive Officer, Biohaven Pharmaceutical Holding Company. Photo Credit: NYSE Elyse Stock, M.D., Chief of Portfolio Strategy and Development
Dr. Stock has more than 30 years of clinical and drug development experience. She was most recently Vice-President Global Development Leader at Bristol-Myers Squibb (BMS), where she worked for the last 19 years in various positions developing numerous investigational agents across multiple therapeutic areas including neuroscience, oncology, immunology and cardiovascular disease. Dr. Stock has led numerous large and complex cross functional programs for both biologics and small molecules across all stages of development, including programs leading to the approvals and marketing of products such as ABILIFY®, subcutaneous ORENCIA®, and EMPLICITI®. Dr. Stock completed her residency at Payne Whitney Clinic, Cornell Medical Center and her fellowship in Child and Adolescent Psychiatry at Children's Hospital National Medical Center in Washington D.C. She earned her medical degree at New York University School of Medicine.
"I am excited to be joining Biohaven at this time, when the company's product candidates have the potential to become best-in-class and first-in-class treatment options for patients with a number of serious and even fatal disorders, including some that are very rare," said Dr. Stock.
Donnie McGrath, M.D., Chief of Corporate Strategy and Business Development
Dr. McGrath has more than 22 years of pharmaceutical industry experience, including the involvement in the execution of numerous in-licensing and out-licensing agreements and business acquisitions. He joins Biohaven from BMS, where he most recently served as Vice President of Business Development and Head of Search & Evaluation. During his leadership role in the business development group at BMS, over 50 major transactions were completed in the therapeutic areas of oncology, neuroscience, cardiovascular, fibrosis, immuno-science, virology, and genetically-defined diseases. In addition, Dr. McGrath was responsible for overseeing BMS' venture capital investment portfolio and provided leadership for all global external partnering activities. Before joining the business development group, Dr. McGrath was the BMS global development lead for REYATAZ®. Dr. McGrath earned his undergraduate degree at University College Dublin, his medical degree from the Royal College of Surgeons in Ireland, and his masters degree in public health from the Harvard School of Public Health. He completed his residency in internal medicine at St. Elizabeth's Medical Center, and a fellowship in infectious disease at Tufts-New England Medical Center, both in Boston.
"It's a pleasure to join this highly entrepreneurial team at this critical point, when Biohaven has the potential, both in terms of talent and financial resources, to make strides in building a wide portfolio of highly innovative therapies," said Dr. McGrath.
Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven has combined internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, ALS Biopharma LLC and Massachusetts General Hospital. Currently, Biohaven's lead development programs include multiple compounds across its CGRP receptor antagonist and glutamate modulation platforms. The company's common shares are listed on the New York Stock Exchange and traded under the ticker symbol BHVN. More information about Biohaven is available at www.biohavenpharma.com.
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's business and product candidate plans and objectives are forward-looking statements. The use of certain words, including the "believe" and "will" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans and objectives disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on June 16, 2017. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Source: Biohaven Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.